Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency - Inria - Institut national de recherche en sciences et technologies du numérique Access content directly
Journal Articles European Journal of Cancer Year : 2023

Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency

Nicolas Pallet
Valérie Boige
  • Function : Author
Laurent Chouchana
Chantal Barin-Le Guellec
  • Function : Author
Aziz Zaanan
  • Function : Author
Céline Narjoz
  • Function : Author
Julien Taieb
  • Function : Author
Fabienne Thomas
Marie-Anne Loriot
  • Function : Author

Abstract

Fluoropyrimidine drugs (FP) are the backbone of many chemotherapy protocols for treating solid tumours. The rate-limiting step of fluoropyrimidine catabolism is dihydropyrimidine dehydrogenase (DPD), and deficiency in DPD activity can result in severe and even fatal toxicity. In this review, we survey the evidence-based pharmacogenetics and therapeutic recommendations regarding DPYD (the gene encoding DPD) genotyping and DPD phenotyping to prevent toxicity and optimize dosing adaptation before FP administration. The French experience of mandatory DPD-deficiency screening prior to initiating FP is discussed
No file

Dates and versions

hal-03934173 , version 1 (11-01-2023)

Identifiers

Cite

Marie-Christine Etienne-Grimaldi, Nicolas Pallet, Valérie Boige, Joseph Ciccolini, Laurent Chouchana, et al.. Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency. European Journal of Cancer, 2023, 181, pp.3-17. ⟨10.1016/j.ejca.2022.11.028⟩. ⟨hal-03934173⟩
15 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More